These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 30421269)

  • 1. BET bromodomain inhibitors: fragment-based in silico design using multi-target QSAR models.
    Speck-Planche A; Scotti MT
    Mol Divers; 2019 Aug; 23(3):555-572. PubMed ID: 30421269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rational drug design for anti-cancer chemotherapy: multi-target QSAR models for the in silico discovery of anti-colorectal cancer agents.
    Speck-Planche A; Kleandrova VV; Luan F; Cordeiro MN
    Bioorg Med Chem; 2012 Aug; 20(15):4848-55. PubMed ID: 22750007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of novel ligand targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery: complete pharmacophore approach.
    Shanmugam V; Muthukrishnan S
    J Biomol Struct Dyn; 2023; 41(23):14524-14539. PubMed ID: 36841551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conformation-dependent QSAR approach for the prediction of inhibitory activity of bromodomain modulators.
    García-Jacas CR; Martinez-Mayorga K; Marrero-Ponce Y; Medina-Franco JL
    SAR QSAR Environ Res; 2017 Jan; 28(1):41-58. PubMed ID: 28161994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. QSAR Modeling for Multi-Target Drug Discovery: Designing Simultaneous Inhibitors of Proteins in Diverse Pathogenic Parasites.
    Kleandrova VV; Scotti L; Bezerra Mendonça Junior FJ; Muratov E; Scotti MT; Speck-Planche A
    Front Chem; 2021; 9():634663. PubMed ID: 33777898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A ligand-based approach for the in silico discovery of multi-target inhibitors for proteins associated with HIV infection.
    Speck-Planche A; Kleandrova VV; Luan F; Cordeiro MN
    Mol Biosyst; 2012 Aug; 8(8):2188-96. PubMed ID: 22688327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.
    Law RP; Atkinson SJ; Bamborough P; Chung CW; Demont EH; Gordon LJ; Lindon M; Prinjha RK; Watson AJB; Hirst DJ
    J Med Chem; 2018 May; 61(10):4317-4334. PubMed ID: 29656650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico study directed towards identification of novel high-affinity inhibitors targeting an oncogenic protein: BRD4-BD1.
    Tumdam R; Kumar A; Subbarao N; Balaji BS
    SAR QSAR Environ Res; 2018 Dec; 29(12):975-996. PubMed ID: 30411639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fragment-based in silico modeling of multi-target inhibitors against breast cancer-related proteins.
    Speck-Planche A; Cordeiro MNDS
    Mol Divers; 2017 Aug; 21(3):511-523. PubMed ID: 28194627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of novel BRD4-BD2 inhibitors via in silico approaches: QSAR techniques, molecular docking, and molecular dynamics simulations.
    Tong JB; Xiao XC; Luo D; Xu HY; Xing YC; Gao P; Liu Y
    Mol Divers; 2024 Apr; 28(2):671-692. PubMed ID: 36773087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of novel 4-phenylisoquinolinone BET bromodomain inhibitors.
    Bennett MJ; Wu Y; Boloor A; Matuszkiewicz J; O'Connell SM; Shi L; Stansfield RK; Del Rosario JR; Veal JM; Hosfield DJ; Xu J; Kaldor SW; Stafford JA; Betancort JM
    Bioorg Med Chem Lett; 2018 Jun; 28(10):1811-1816. PubMed ID: 29657099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies.
    Jiang F; Wei Q; Li H; Li H; Cui Y; Ma Y; Chen H; Cao P; Lu T; Chen Y
    Bioorg Med Chem; 2020 Jan; 28(1):115181. PubMed ID: 31767403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery.
    Chung CW; Dean AW; Woolven JM; Bamborough P
    J Med Chem; 2012 Jan; 55(2):576-86. PubMed ID: 22136404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigations of Structural Requirements for BRD4 Inhibitors through Ligand- and Structure-Based 3D QSAR Approaches.
    Tahir A; Alharthy RD; Naseem S; Mahmood N; Ahmed M; Shahzad K; Akhtar MN; Hameed A; Sadiq I; Nawaz H; Muddassar M
    Molecules; 2018 Jun; 23(7):. PubMed ID: 29941841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.
    Sperandio D; Aktoudianakis V; Babaoglu K; Chen X; Elbel K; Chin G; Corkey B; Du J; Jiang B; Kobayashi T; Mackman R; Martinez R; Yang H; Zablocki J; Kusam S; Jordan K; Webb H; Bates JG; Lad L; Mish M; Niedziela-Majka A; Metobo S; Sapre A; Hung M; Jin D; Fung W; Kan E; Eisenberg G; Larson N; Newby ZER; Lansdon E; Tay C; Neve RM; Shevick SL; Breckenridge DG
    Bioorg Med Chem; 2019 Feb; 27(3):457-469. PubMed ID: 30606676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Theoretically exploring selective-binding mechanisms of BRD4 through integrative computational approaches.
    Luo D; Tong JB; Xiao XC; Bian S; Zhang X; Wang J; Xu HY
    SAR QSAR Environ Res; 2021 Dec; 32(12):985-1011. PubMed ID: 34845959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unified QSAR approach to antimicrobials. Part 3: first multi-tasking QSAR model for input-coded prediction, structural back-projection, and complex networks clustering of antiprotozoal compounds.
    Prado-Prado FJ; González-Díaz H; de la Vega OM; Ubeira FM; Chou KC
    Bioorg Med Chem; 2008 Jun; 16(11):5871-80. PubMed ID: 18485714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
    Ran X; Zhao Y; Liu L; Bai L; Yang CY; Zhou B; Meagher JL; Chinnaswamy K; Stuckey JA; Wang S
    J Med Chem; 2015 Jun; 58(12):4927-39. PubMed ID: 26080064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular docking and dynamics simulation study of flavonoids as BET bromodomain inhibitors.
    Raj U; Kumar H; Varadwaj PK
    J Biomol Struct Dyn; 2017 Aug; 35(11):2351-2362. PubMed ID: 27494802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fragment-based in silico screening of bromodomain ligands.
    Spiliotopoulos D; Caflisch A
    Drug Discov Today Technol; 2016 Mar; 19():81-90. PubMed ID: 27769362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.